Kaiser Permanente's prescription drug benefit.

Abstract

Health Tracking Health AffairsVol. 19, No. 2 Kaiser Permanente's Prescription Drug BenefitSharon Levine, David Campen, Mirta Millares, and Anthony Barrueta AffiliationsSharon Levine, a physician, is associate executive director of the Permanente Medical Group in Oakland, California. David Campen, also a physician, chairs the formulary subcommittee of the Permanente Medical Group. Mirta Millares is manager, drug information, in the Kaiser Foundation Health Plan's Drug Information and Professional Services, California Division. Anthony Barrueta is counsel, government relations, at the Kaiser Foundation Health Plan in Oakland.PUBLISHED:March/April 2000No Accesshttps://doi.org/10.1377/hlthaff.19.2.185AboutSectionsView articleView Full TextView PDFPermissions ShareShare onFacebookTwitterLinked InRedditEmail ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions View articleTOPICSPharmaceuticalsFormulariesPrescription drugsMarketsOrganization of careDrug benefitsPrescription drug costsCosts and spendingValueQuality of care Loading Comments... Please enable JavaScript to view the comments powered by Disqus. DetailsExhibitsReferencesRelated Article MetricsCitations: Crossref 16 History Published online 1 March 2000 InformationCopyright © by Project HOPE: The People-to-People Health Foundation, Inc.PDF downloadCited byProcess-Based Treatment of Diabetes in Kaiser Permanente Southern California: How to Make Diabetes Care “Complete”2 August 2017 | Current Diabetes Reports, Vol. 17, No. 9Pharmaceutical Sales Representatives and Patient Safety25 July 2013 | Journal of General Internal Medicine, Vol. 28, No. 11Potential Savings of Harmonising Hospital and Community Formularies for Chronic Disease Medications Initiated in Hospital26 June 2012 | PLoS ONE, Vol. 7, No. 6Assessing the effects of drug price reduction policies on older people in Taiwan1 February 2011 | Health Services Management Research, Vol. 24, No. 1Policies and institutional arrangements for rationalizing drug selection and consumption patterns in African healthcare systemsResearch in Social and Administrative Pharmacy, Vol. 5, No. 3The impact of direct-to-consumer advertised drugs on drug sales in the US and New Zealand6 August 2012 | Applied Health Economics and Health Policy, Vol. 6, No. 2-3Reducing Drug Costs at a Veterans Affairs Hospital by Increasing Market-share of Generic Fluoxetine22 September 2006 | Community Mental Health Journal, Vol. 43, No. 1Treatment Regimen and Childhood Asthma: Implications for the Income Gradient in HealthSSRN Electronic JournalKaiser Permanente’s Evaluation And Management Of Biotech Drugs: Assessing, Measuring, And Affecting UseC. Douglas Monroe, Lori Potter, Mirta Millares, Anthony Barrueta, and Richard Wagner2 August 2017 | Health Affairs, Vol. 25, No. 5Risk of Hospitalization for Heart Failure Associated with Thiazolidinedione Therapy: A Medicaid Claims–Based Case-Control StudyPharmacotherapy, Vol. 25, No. 10Provider Perceptions of Pharmacy ManagementMedical Care, Vol. 42, No. 4The Perfect StormPsychiatric Annals, Vol. 34, No. 2Benefit Plan Design and Prescription Drug Utilization Among Asthmatics: Do Patient Copayments Matter?Forum for Health Economics & Policy, Vol. 7, No. 1An Ethical Template For Pharmacy BenefitsNorman Daniels, J. Russell Teagarden, and James E. Sabin17 August 2017 | Health Affairs, Vol. 22, No. 1New Directions in Pharmacoeconomic Research: The Next Step31 December 2002 | Drug Information Journal, Vol. 36, No. 4The Bleeding Edge of Decision Making in Managed Health Care—Kaiser-Permanente's Model for Formulary DevelopmentValue in Health, Vol. 5, No. 5